Related Experiment Videos
Inhaled beta2-agonists for treating non-specific chronic cough in children
A A T Tomerak1, H Vyas, M Lakenpaul
1Department of Child Health, Queen's Medical Centre, Nottingham, UK. ahmedtomerak@hotmail.com
The Cochrane Database of Systematic Reviews
|July 22, 2005
Summary
Inhaled short-acting beta2 agonists (salbutamol) did not significantly reduce chronic cough in children over two years old. This study found no difference compared to placebo for cough variant asthma treatment.
Area of Science:
- Pediatric Pulmonology
- Clinical Pharmacology
Background:
- Cough variant asthma's pathophysiology is poorly understood, with debate on its classification.
- Proponents suggest asthma medications for cough variant asthma, but evidence is limited.
Purpose of the Study:
- To evaluate the efficacy of inhaled short-acting beta2 agonists (SS2A) for treating non-specific chronic cough in children over two years old.
Main Methods:
- Comprehensive literature search of databases (MEDLINE, EMBASE, CINAHL, CCRT) and grey literature.
- Inclusion of randomized controlled trials comparing inhaled SS2A to placebo in children with chronic cough.
- Independent assessment of study inclusion and quality by two reviewers, with data extraction using Review Manager software.
Main Results:
- No significant difference was observed between the salbutamol group and the placebo group in reducing isolated chronic cough frequency in children.
- Objective and subjective measures of cough reduction showed no statistically significant improvement with salbutamol treatment.
Conclusions:
- Inhaled salbutamol demonstrated no significant benefit over placebo in alleviating chronic cough in children over two years of age.
- The findings do not support the use of inhaled short-acting beta2 agonists for treating chronic cough in this pediatric population.